929094-25-7

Basic information

• Product Name: 1-Isobutyl-1H-pyrazole-4-boronic acid
• Synonyms: 1-Isobutyl-1H-pyrazole-4-boronic acid;(1-Isobutyl-1H-pyrazol-4-yl)boronic acid
• CAS NO: 929094-25-7
• Molecular Formula: C7H13BN2O2
• Molecular Weight: 168.00132
• Mol File: 929094-25-7.mol
• Article Data: 1

Chemical Properties

• Boiling Point: 330.6±34.0 °C(Predicted)
• Appearance: /
• Density: 1.12±0.1 g/cm3(Predicted)
• Storage Temp.: Keep in dark place,Inert atmosphere,Store in freezer, under -20°C
• PKA: 7.75±0.10(Predicted)
• CAS DataBase Reference: 1-Isobutyl-1H-pyrazole-4-boronic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 1-Isobutyl-1H-pyrazole-4-boronic acid(929094-25-7)
• EPA Substance Registry System: 1-Isobutyl-1H-pyrazole-4-boronic acid(929094-25-7)

Safety Data

• Hazardous Substances Data: 929094-25-7(Hazardous Substances Data)

Usage

General Description

1-Isobutyl-1H-pyrazole-4-boronic acid is a chemical compound that belongs to the boronic acid family. It has the molecular formula C8H14BNO2 and a molecular weight of 155.01 g/mol. 1-Isobutyl-1H-pyrazole-4-boronic acid is commonly used in organic synthesis and medicinal chemistry as a building block for the synthesis of various pharmaceuticals and agrochemicals. It is a versatile reagent in Suzuki-Miyaura coupling reactions, which is a valuable tool in the formation of carbon-carbon bonds. Additionally, 1-Isobutyl-1H-pyrazole-4-boronic acid has been studied for its potential biological activities and is being investigated for its potential anti-cancer properties.

Downstream Products

• 1160703-71-8 6-(1-isobutyl-1H-pyrazol-4-yl)-N-(4-(trifluoromethoxy)phenyl)pyrimidin-4-amine 

Relevant articles and documents

INHIBITORS OF FATTY ACID AMIDE HYDROLASE

The present invention provides compounds, and pharmaceutically acceptable compositions thereof, encompassed by any of formulae (I), (II), (III), (IV), (V), or (VI), or subgenera thereof. The present invention also provides methods for treating an FAAH mediated disease, disorder or condition by administering a therapeutically effective amount of a compound or composition comprising a compound of any of formulae (I), (II), (III), (IV), (V), or (VI), or subgenera thereof, to a patient in need thereof. Additionally, the present invention provides methods for inhibiting FAAH by administering a therapeutically effective amount of a compound or composition comprising a compound of any of formulae (I), (II), (III), (IV), (V), or (VI), or subgenera thereof, to a patient in need thereof.